Clinic Roundup

• Patrys Ltd., of Melbourne, Australia, said it completed initial treatment of the first group of three patients in its Phase I/IIa PAT-SM6 multiple myeloma trial. Each patient received four doses of the lead antibody candidate at a dose of 0.3 mg/kg, and no significant safety issues have been observed or reported to date.